• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Show me the money: Reimbursement for medical innovations

Show me the money: Reimbursement for medical innovations

April 3, 2015 By MassDevice Contributors Network

By Nancy Fliesler

Device developers tend to focus on the FDA approval process – PMAs and 510(k) clearances – while overlooking another major challenge: getting insurers to cover the device. Before approaching investors, and certainly before doing any studies, keep payers in mind, advises Maren Anderson, president of MDA Consulting, Inc., which specializes in reimbursement planning.

In the old days, doctors prescribed, and insurers paid. Under health care reform, that’s changed, says Anderson. She elaborated at a Boston Children’s Hospital forum last week, sponsored by the Innovation Acceleration Program.

Take a diagnostic test, for example. The FDA wants to see data on the test’s sensitivity and specificity. But insurers want more: they want evidence that the product will solve a real clinical problem and reduce overall costs. Will it allow patients to avoid surgery or be discharged earlier from the hospital? “Insurers are increasingly demanding outcomes data,” Anderson says.

Vector

A great specific example is intravascular optical coherence tomography (OCT), a type of high-resolution imaging to diagnose “vulnerable plaques” – those likely to lead to heart attacks or sudden cardiac death – and identify heart patients in need of stenting. Several OCT devices have received 510(k) marketing clearance, but Medicare does not currently pay for OCT. To convince Medicare, a study would need to track patients who are stented based on OCT findings and show that their outcomes are improved. “The developers will have to team up with a big stent company to get this done,” says Anderson.

A well-designed study

Gathering good data early on will also help in attracting funding from venture capitalists (VCs), who want quick evidence that their investment will be a success. “The VC wants to get in and get out with one study,” Anderson says. “But if there is just one study, it needs to satisfy not just FDA requirements but payer requirements.”

As an alternative to approaching payers, innovators can approach at-risk providers – hospitals or health care systems that are under a bundled or global payment plan, or any other arrangement that shifts financial risk to the provider. Since these providers receive a fixed payment for an episode of care or a whole patient population, “they want to see an innovation lowering their cost and improving quality,” says Anderson.

Innovators inside a hospital or care network who understand the cost and quality issues have a natural advantage here, especially when it comes to health care IT. And sometimes you can do a trial just to convince an at-risk provider, Anderson notes.

Here are some things that studies should do:

  • Document long-term clinical and cost outcomes. Payers want to know “does it make a difference in a patient’s life for more than one year?” Follow-up studies are often required, and some payers want to see Phase 3 trials.
  • Provide enough data to make the device the new gold standard (usually, multiple studies will be needed).
  • Identify a specific population who will benefit. “Insurers don’t want people coming out of the woodwork to get the device; they want to narrow the population as much as they possibly can,” says Anderson.

It can sometimes make sense to segment the insurance market. When Medicare or Medicaid won’t cover something, sometimes other insurers will, as in the case of the BiOM prosthetic ankle (demonstrated at a TED talk by a ballroom dancer who lost a lower leg in the Boston Marathon bombings). BiOM has not been able to get Medicare coverage, but the Veterans Administration does cover the $50,000 bionic device, as do some private workers’ compensation payers.

A few other reimbursement tips:

  • Consult with insurers before you do a study, so you can build in the right endpoints.
  • If you’re looking for Medicare to cover the device, include patients over 65 in your studies.
  • Software is rarely covered by insurance, but you might be able to convince an at-risk provider to pay for it if it can lower costs and improve quality.
  • If possible, consider patient self-pay – marketing directly to the consumer. “If you have that option, VCs are going to love you,” Anderson says.
  • In pricing your device, “leave some money on the table,” thinking about what patients can afford.

Help may be available

In trying to persuade an insurer to cover an innovation, Anderson advises looking to opinion leaders, patients, specialty societies and trade organizations like AdvaMed and the Medical Device Manufacturers Association as allies.

To offset development costs, the Affordable Care Act provides grant money for innovations that improve care and lower costs for people enrolled in Medicare, Medicaid and the Children’s Health Insurance Program (CHIP), particularly those with the highest health care needs. Specific interests include:

  • independence (products or systems that let sick people live at home)
  • improved primary care delivery
  • improved long-term care services
  • enhanced community care
  • improvements in trauma centers

For more practical innovation take-homes, join a mix of clinicians, health care leaders, payers, venture capitalists, policymakers and other stakeholders attending the 2015 Global Pediatric Innovation Summit + Awards (Nov. 9-10).

Filed Under: Big Data, Blog, News Well Tagged With: Boston Children's Hospital, Vector Blog

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy